

1ISG-015

L04 – IMMUNOSUPPRESSIVE AGENTS

Domínguez Barahona, A; Fernandez-Corada Sanchez, A; Garcia Sacristán, A; Gonzalez Suarez, S; Lopez Alvarez, R; Blazquez Romero, C; Labrador Andújar, N; Moya Gomez, P.
HOSPITAL VIRGEN DE LA SALUD, PHARMACY, TOLEDO, SPAIN.

PURPOSE

To analyze patients with psoriasis on an optimized pattern of biological treatment and to estimate the annual saving of these optimized patterns in a third level hospital.

MATERIALS AND METHODS

Observational, retrospective and longitudinal study of psoriasis patients treated with biologic drugs in a general hospital of 650 beds. Medical records review and a retrospective analysis of prescriptions registered in the Integral external Patient Information System and in the computerized History System was done to **30th September 2018**.

We recorded demographic data (age, sex), type of biological therapy, clinical control of disease, optimized therapy yes/no and the annual economic impact due to every drug on an optimized pattern.

RESULTS

150 patients diagnosed with psoriasis were included, **102 (68%) men and 48 (32%) women**, aged between 9 and 87 years (-median **46,8 years**-).

Patient distribution according to the biologic drug used, number of patients on an optimized treatment patterns and the estimated saving per patient per year are included in the figure above:

BIOLOGICAL DRUG	TOTAL PACIENTS	OPTIMIZED THERAPHY PATIENTS	ESTIMATED SAVING PER PATIENT PER YEAR (€)	ESTIMATED SAVING PER YEAR (€)
Etanercept	7	3 (42,86%)	3700*	11200
Adalimumab	33	11 (33,35)	4600*	50900
Ustekinumab	73	23	7200*	62000
Secukinumab	15	6	4000*	23900
Ixekizumab	7	1	2300	2300
Apremilast	15	4	4200*	16900
Total	150	48 (32%)*		167.200

*median

48 patients (32%) were in treatment with an optimized biological therapy pattern.

It is estimated that with these optimized biological therapies the annual saving is around 160.000 euros.

CONCLUSIONS

The number of our patients receiving individualized biological treatment for psoriasis is more than a third, which allows getting the same clinical effects with less economic impact on our Health System.

The estimated savings per year in our hospital due to optimized biological treatments for psoriasis is important because quality of treatment is not affected.